BioCentury
ARTICLE | Company News

Aridis, Shenzhen Hepalink form China JV

March 9, 2018 7:10 PM UTC

Aridis Pharmaceuticals Inc. (San Jose, Calif.) and Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399) formed a JV -- Shenzhen Arimab Biopharmaceuticals Co. Ltd. -- to develop and gain regulatory approval of two of Aridis’ candidates, Salvecin (AR-301, kbsa301) and Aerumab panobacumab (AR-101, kbpa101) in China.

Aridis said the JV "will be launched with significant capital commitment" and that ownership of the JV will be roughly equal. According to Aridis, it is providing license rights and other support while Hepalink is contributing capital. The company did not provide details...